When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Melioidosis and glanders

Evidence last reviewed: 17 Aug 2026
Topic last updated: 23 Aug 2023

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • fever/sweats
  • cough
  • septic shock
  • regional lymphadenitis/parotitis
  • non-healing skin sore/ulcer or abscess
  • bacteraemia without evident clinical focus
  • lower motor neuron cranial nerve palsies (especially cranial nerves VII and VIII)
  • flaccid paralysis
Full details

Other diagnostic factors

  • dyspnoea
  • abdominal pain/diarrhoea
  • dysuria
  • urinary retention
  • other signs of organ abscess
  • altered conscious state
  • arthritis/osteomyelitis
  • mycotic pseudo-aneurysms
Full details

Risk factors

  • travel to endemic area
  • occupational/recreational environmental exposure
  • diabetes mellitus
  • hazardous alcohol use
  • chronic renal or liver disease
  • malignancy and immunosuppressive therapy
  • thalassaemia
  • cystic fibrosis and other chronic lung disease
  • bioterrorism
Full details

Diagnostic investigations

1st investigations to order

  • blood culture
  • sputum culture
  • urine culture
  • culture of pus/swab from skin lesion, abscess, lymphadenitis, drained internal abscess
  • chest x-ray
  • CT abdomen and pelvis ± chest
  • abdominal/pelvis ultrasound
Full details

Investigations to consider

  • throat swab in/on Ashdown's selective broth/agar
  • rectal swab in/on Ashdown's selective broth/agar
  • cerebrospinal fluid (CSF) culture
  • cerebrospinal fluid (CSF) microscopy, protein and glucose
  • polymerase chain reaction (PCR)
Full details

Emerging tests

  • rapid antigen detection test

Treatment algorithm

ACUTE

non-localised disease or patient systemically unwell

localised skin disease

ONGOING

intensive intravenous antibiotic therapy completed; localised skin disease responsive to oral eradication therapy

Contributors

Authors

Bart J. Currie, MBBS, FRACP, FAFPHM, DTM+H, PhD

Professor in Medicine

Northern Territory Medical Program

Royal Darwin Hospital

Head of Tropical and Emerging Infectious Diseases

Menzies School of Health Research

Charles Darwin University

Darwin

Australia

Disclosures

BJC declares that he has no competing interests.

Ella Meumann, MBBS (Hons), DTM&H, FRACP, FRCPA, PhD

Infectious Diseases Physician and Medical Microbiologist

Royal Darwin Hospital

Darwin

Australia

Disclosures

EM declares that she has no competing interests.

Acknowledgements

Dr Bart J. Currie and Dr Ella Meumann would like to gratefully acknowledge Professor David Dance, a previous contributor to this topic.

Disclosures

DD acted as a consultant to InBios International Inc. (in relation to the development of rapid diagnostic tests for melioidosis), and to MerLion Pharmaceuticals and Venatorx Pharmaceuticals (in relation to the development of novel therapies for melioidosis).

Peer reviewers

Robert Norton, MBBCh (Hons), MRCP (UK), FRCPA, MD

Director of Microbiology

Townsville Hospital

Townsville

Australia

Disclosures

RN declares that he has no competing interests.

Ploenchan Chetchotisakd, MD

Professor of Medicine

Faculty of Medicine

Khon Kaen University

Khon Kaen

Thailand

Disclosures

PC declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med. 2001 Jul 26;345(4):256-8.Full text  Abstract

Currie BJ, Janson S, Meumann EM, et al. The 2024 revised Darwin melioidosis treatment guideline. The Northern Territory Disease Control Bulletin, 2023 Dec;30(4).Full text

Hoffmaster AR, AuCoin D, Baccam P, et al. Melioidosis diagnostic workshop, 2013. Emerg Infect Dis. 2015 Feb;21(2):e141045.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Use of this content is subject to our disclaimer